US › Healthcare

Rein Therapeutics Inc (RNTX)

US · Healthcare · Biotechnology

$0.76+2.44%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-5.8M

Profit YoY

-6.1%

EPS

$-0.19

EPS estimate

$-0.49

EPS came in at -0.19 against a street estimate of -0.49 — a beat of 61.2%.

Key statistics

Market cap

$63.1M

Forward P/E

0.0

P/B

28.17

Book value

$-1.19

EPS (TTM)

$-1.91

52-week high

$2.18

52-week low

$0.72

50-day MA

$0.94

200-day MA

$1.23

Beta

1.35

Analyst view

Analysts rate Rein Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $6.00.

Shareholding

Insiders

5.37%

Institutions

20.85%

Largest institutional holders

Fund	Stake
Voss Capital LLC	5.13%
BIOS CAPITAL MANAGEMENT, LP	2.32%
Vanguard Capital Management, LLC	1.17%
University Of Texas Investment Mgmt Co	0.60%
Cable Car Capital LLC	0.49%
Prosight Management, LP	0.48%
Sigma Planning Corp	0.41%
Geode Capital Management, LLC	0.40%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rein Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.